Glenmark Pharmaceuticals Ltd. (Glenmark), a research-led, global pharmaceutical company, announced its consolidated financial results for the second quarter ended September 30, 2025.

Glenmark posted Q2 FY26 revenue of Rs. 6,046.9 crore as against Rs. 3,433.8 crore in the corresponding quarter last year, recording an increase of 76.1 per cent YoY.

EBITDA was Rs. 2,359.6 crore in the quarter ended September 30, 2025, as compared to Rs. 601.9 crore in the corresponding quarter of the previous year, registering growth of 292 per cent and an EBITDA margin of 39 per cent.

Profit After Tax (PAT) for the quarter was Rs. 610.4 crore, up 72.2 per cent YoY, with a PAT margin of 10.1 per cent.

While Europe revenue was up by 8.5 per cent YoY to Rs. 746 crore, North America business grew by 7.4 per cent (net of the out-licensing income of the ISB 2001 deal) in Q2FY26. During the quarter, India formulations revenue stood at Rs. 165 crore and emerging markets revenue was at Rs. 658.5 crore.

Commenting on the results, Glenn Saldanha, Chairman & Managing Director, Glenmark Pharmaceuticals Ltd. said, "Q2FY26 reflects the steady progress we are making in strengthening Glenmark's scientific and strategic foundation. The AbbVie partnership for ISB 2001, along with the income recognised this quarter, is a significant validation of our scientific strength and enables us to advance the pipeline in a financially self-sustaining way.

“Across key markets, our performance remained resilient. North America delivered a continued uptick in performance, supported by the expansion of our injectable portfolio and steady execution across institutional channels. Europe returned to its growth trajectory, backed by recent product launches.

“In India, GST-related adjustments, given our unique three-tiered distribution model, had a one-time impact on primary sales; however secondary sales continue to outperform IPM, and we expect reported growth to normalize from Q3 onwards.

"Our specialty and innovation businesses progressed several important milestones this quarter including the global expansion of RYALTRIS, the UK launch of WINLEVI, the regulatory and clinical milestones achieved for QiNHAYOTM, and our IGI oncology assets. We remain committed to disciplined execution, advancing meaningful science, and delivering sustained value for our patients, partners, and all stakeholders."